<?xml version="1.0" encoding="UTF-8"?>
<p>An antibody that causes ADE can be defined as one which binds viral particles but does not prevent viral entry into host cells [
 <xref rid="B51-vaccines-07-00203" ref-type="bibr">51</xref>,
 <xref rid="B65-vaccines-07-00203" ref-type="bibr">65</xref>]. This is dependent not only on whether it binds to neutralising epitopes, but also circulating levels, its affinity, and how accessible the epitope is [
 <xref rid="B14-vaccines-07-00203" ref-type="bibr">14</xref>,
 <xref rid="B64-vaccines-07-00203" ref-type="bibr">64</xref>,
 <xref rid="B81-vaccines-07-00203" ref-type="bibr">81</xref>,
 <xref rid="B82-vaccines-07-00203" ref-type="bibr">82</xref>,
 <xref rid="B83-vaccines-07-00203" ref-type="bibr">83</xref>,
 <xref rid="B84-vaccines-07-00203" ref-type="bibr">84</xref>]. As such a neutralising antibody could theoretically become disease enhancing in low levels [
 <xref rid="B14-vaccines-07-00203" ref-type="bibr">14</xref>,
 <xref rid="B64-vaccines-07-00203" ref-type="bibr">64</xref>,
 <xref rid="B81-vaccines-07-00203" ref-type="bibr">81</xref>,
 <xref rid="B82-vaccines-07-00203" ref-type="bibr">82</xref>,
 <xref rid="B83-vaccines-07-00203" ref-type="bibr">83</xref>,
 <xref rid="B84-vaccines-07-00203" ref-type="bibr">84</xref>]. A key factor is cross-reactivity (heterotypic) with the secondary infecting serotype, but heterotypic antibodies can be neutralising [
 <xref rid="B85-vaccines-07-00203" ref-type="bibr">85</xref>] and heterotypic neutralising antibodies have been associated with reduced symptoms [
 <xref rid="B86-vaccines-07-00203" ref-type="bibr">86</xref>].
</p>
